JP2007106777A5 - - Google Patents

Download PDF

Info

Publication number
JP2007106777A5
JP2007106777A5 JP2007017195A JP2007017195A JP2007106777A5 JP 2007106777 A5 JP2007106777 A5 JP 2007106777A5 JP 2007017195 A JP2007017195 A JP 2007017195A JP 2007017195 A JP2007017195 A JP 2007017195A JP 2007106777 A5 JP2007106777 A5 JP 2007106777A5
Authority
JP
Japan
Prior art keywords
desloratadine
mometasone furoate
medicament
use according
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007017195A
Other languages
English (en)
Other versions
JP2007106777A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2007106777A publication Critical patent/JP2007106777A/ja
Publication of JP2007106777A5 publication Critical patent/JP2007106777A5/ja
Pending legal-status Critical Current

Links

Claims (10)

  1. デスロラタジンおよびモメタゾンフロエートの局所適用を含む併用療法により鼻炎を治療するための医薬の製造における、デスロラタジンの使用。
  2. デスロラタジンおよびモメタゾンフロエートの局所適用を含む併用療法により鼻炎を治療するための医薬の製造における、モメタゾンフロエートの使用。
  3. 請求項1または請求項2のうちのいずれかに記載の使用であって、前記デスロラタジンおよびモメタゾンフロエートが別個の投薬形状で存在していることを特徴とする、使用。
  4. 請求項1または請求項2のうちのいずれかに記載の使用であって、前記デスロラタジンおよびモメタゾンフロエートが単位投薬形状で存在していることを特徴とする、使用。
  5. 請求項1〜4のうちのいずれか1項に記載の使用であって、前記医薬が水性スプレー式点鼻薬の形状であることを特徴とする、使用。
  6. 請求項1〜4のうちのいずれか1項に記載の使用であって、前記医薬が加圧計量用量吸入器の形状であることを特徴とする、使用。
  7. 薬学的に受容可能な担体中にデスロラタジンおよびモメタゾンフロエートを含有することを特徴とする、流体組成物。
  8. 請求項7に記載の組成物であって、前記デスロラタジンおよびモメタゾンフロエートのうちの一方または両方が懸濁した粒子として存在していることを特徴とする、使用。
  9. 請求項7または請求項8のうちのいずれかに記載の組成物であって、前記担体が水性媒体を含有することを特徴とする、組成物。
  10. 請求項7または請求項8のうちのいずれかに記載の組成物であって、前記担体が低沸点クロロフルオロカーボン噴霧剤または低沸点フルオロハイドロカーボン噴霧剤を含有することを特徴とする、組成物。
JP2007017195A 1999-10-08 2007-01-26 局所的鼻疾患治療 Pending JP2007106777A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41508399A 1999-10-08 1999-10-08

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2001529720A Division JP2003511417A (ja) 1999-10-08 2000-10-05 局所的鼻疾患治療

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007295933A Division JP2008056698A (ja) 1999-10-08 2007-11-14 局所的鼻疾患治療

Publications (2)

Publication Number Publication Date
JP2007106777A JP2007106777A (ja) 2007-04-26
JP2007106777A5 true JP2007106777A5 (ja) 2007-12-27

Family

ID=23644317

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2001529720A Withdrawn JP2003511417A (ja) 1999-10-08 2000-10-05 局所的鼻疾患治療
JP2007017195A Pending JP2007106777A (ja) 1999-10-08 2007-01-26 局所的鼻疾患治療
JP2007295933A Pending JP2008056698A (ja) 1999-10-08 2007-11-14 局所的鼻疾患治療

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2001529720A Withdrawn JP2003511417A (ja) 1999-10-08 2000-10-05 局所的鼻疾患治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2007295933A Pending JP2008056698A (ja) 1999-10-08 2007-11-14 局所的鼻疾患治療

Country Status (9)

Country Link
EP (1) EP1227812B1 (ja)
JP (3) JP2003511417A (ja)
AR (1) AR025964A1 (ja)
AT (1) ATE359784T1 (ja)
AU (1) AU7859800A (ja)
CA (1) CA2383970A1 (ja)
DE (1) DE60034476T2 (ja)
ES (1) ES2284531T3 (ja)
WO (1) WO2001026658A2 (ja)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003101434A2 (en) * 2001-12-21 2003-12-11 Sampad Bhattacharya Intranasal pharmaceutical compositions comprising an antihistamine and a leukotriene inhibitor
TR200201343A2 (tr) * 2002-05-17 2003-12-22 Orva İlaç Sanayi̇ Ve Ti̇caret A. Ş. Kortikosteroid ve antiseptik içeren farmasötik bileşim
EP1560586A1 (en) * 2002-11-12 2005-08-10 Alcon, Inc. The use of an anti-allergy agent and a steroid to treat allergic rhinitis
CA2518960C (en) 2003-03-14 2013-08-27 Sinexus, Inc. Sinus delivery of sustained release therapeutics
WO2004082589A2 (en) * 2003-03-20 2004-09-30 Ranbaxy Laboratories Limited Nasally administrable, bioavailable pharmaceutical composition of loratadine
TW200522932A (en) * 2003-09-15 2005-07-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
WO2006058022A1 (en) 2004-11-24 2006-06-01 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
CA2603081C (en) 2005-04-04 2013-09-03 Sinexus, Inc. Device and methods for treating paranasal sinus conditions
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
WO2008008373A2 (en) 2006-07-11 2008-01-17 Arubor Corp Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
DE102006034883A1 (de) * 2006-07-25 2008-01-31 Hermal Kurt Herrmann Gmbh & Co. Ohg Pharmazeutische Zusammensetzung enthaltend Mometasonfuroat
US20090325917A1 (en) * 2006-10-19 2009-12-31 Cipla Limited Pharmaceutical Compositions and Nasal Spray Incorporating Anhydrous Mometasone Furoate
AU2008338586B2 (en) 2007-12-18 2015-01-29 Intersect Ent, Inc. Self-expanding devices and methods therefor
WO2010014834A1 (en) 2008-08-01 2010-02-04 Sinexus, Inc. Methods and devices for crimping self-expanding devices
KR101099826B1 (ko) 2009-02-16 2011-12-27 서울대학교산학협력단 항알러지성 약물을 활성성분으로 함유하는 비강투여용 액상제제
EP3103502A1 (en) 2009-05-15 2016-12-14 Intersect ENT, Inc. Expandable devices and methods therefor
WO2011141929A2 (en) 2010-05-11 2011-11-17 Cadila Healthcare Limited Aqueous pharmaceutical compositions of fluticasone and olopatadine
FR2970180B1 (fr) * 2011-01-06 2013-08-02 Substipharm Dev Procede de preparation de suspensions aqueuses pharmaceutiques comprenant un medicament efficace dans le traitement des rhinites
DE112011105633T5 (de) 2011-09-21 2014-08-28 Mitsubishi Electric Corp. Siliziumkarbidhalbleitervorrichtung und Verfahren zu ihrer Herstellung
AU2014236729B2 (en) 2013-03-14 2018-11-22 Intersect Ent, Inc. Systems, devices, and method for treating a sinus condition
US9937189B2 (en) 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
EP3043773B1 (en) 2013-09-13 2021-06-30 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine for nasal administration
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
CN105792828A (zh) 2013-10-04 2016-07-20 格兰马克药品有限公司 使用莫米松和奥洛他定的组合治疗过敏性鼻炎
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10016443B2 (en) 2013-10-04 2018-07-10 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10548907B2 (en) 2013-10-04 2020-02-04 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10653661B2 (en) 2013-10-04 2020-05-19 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US11679210B2 (en) 2014-10-03 2023-06-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
US20160120928A1 (en) * 2014-11-03 2016-05-05 Zent, Inc. Nasal spray
ES2802530T3 (es) * 2015-08-04 2021-01-20 Windstar Medical Gmbh Una composición nasal
CN106619504A (zh) * 2016-11-10 2017-05-10 北京万全德众医药生物技术有限公司 一种地氯雷他定口服滴剂及其制备方法
CN111787954B (zh) * 2018-02-23 2023-09-05 格兰马克专业公司 使用莫美他松和奥洛他定的组合治疗儿科受试者的过敏性鼻炎
JP7337791B2 (ja) * 2018-06-22 2023-09-04 参天製薬株式会社 デスロラタジン又はその塩を含有する医薬組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE246497T1 (de) * 1991-06-10 2003-08-15 Schering Corp Fluorchlorkohlenwasserstoffreie aerosolformulierungen
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US5595997A (en) * 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
EP0780127A1 (en) * 1995-12-19 1997-06-25 The Procter & Gamble Company A nasal spray containing a steroid and a antihistamine
CA2256721A1 (en) * 1996-06-04 1997-12-11 The Procter & Gamble Company A nasal spray containing an intranasal steroid and an antihistamine
US5939426A (en) * 1997-02-28 1999-08-17 Sepracor Inc. Methods for treating urinary incontinence using descarboethoxyloratadine
JP2001510485A (ja) * 1999-03-01 2001-07-31 シェーリング コーポレイション アトピー性皮膚炎、血管性浮腫および他の障害を抗ヒスタミン薬およびグルココルチコイドを用いて処置するための組成物および方法

Similar Documents

Publication Publication Date Title
JP2007106777A5 (ja)
JP2010132695A5 (ja)
JP2014530231A5 (ja)
HRP20130835T1 (hr) Farmaceutske formulacije otopine za davanje kao stlaäśeni inhalat u inhalatoru
JP2013224331A5 (ja)
CL2009000601A1 (es) Composicion farmaceutica inhalable en forma de polvo seco que comprende bromuro de aclidinio y un vehiculo, que proporciona una dosis nominal medida de aclinio equivalente a aproximadamente 200 ug de bromuro de aclinio; su uso en epoc y asma; dispositivo inhalador de polvo seco multidosis.
JP2014528470A5 (ja)
JP2011520911A5 (ja)
HRP20151214T4 (hr) Pripravak za inhalaciju koji sadrži aklidinij za liječenje kronične opstruktivne plućne bolesti
ECSP14028814A (es) Nueva forma de dosificación y formulación de abediterol
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
EA201201397A1 (ru) Ингалятор, содержащий расслаиваемую блистерную упаковку
CL2014003211A1 (es) Composicion farmaceutica para inhalacion que comprende aclidinio, con lactosa, que proporciona una dosis de 322 ug de base libre y aprox 140 ug de bromuro de aclidinio; un metodo para tratar una afeccion respiratoria seleccionada de asma y epoc; uso de la composicion; y un dispositivo inhalador de polvo seco calibrado que la comprende
JP2014504636A5 (ja)
RS53821B1 (en) INHALATION PHARMACEUTICAL COMPOSITION
CY1117596T1 (el) Φαρμακευτικeς συνθeσεις αερολyματος φορμοτερολης και διπροπιονικης βεκλομεθαζονης
JP2014520874A5 (ja)
WO2011093815A3 (en) Pharmaceutical compositions comprising formoterol and mometasone
EA201201390A1 (ru) Кнопочное устройство мундштука ингалятора сухого порошка
CO6270213A2 (es) Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion
JP2011500731A5 (ja)
JP2015536334A5 (ja)
HRP20221034T1 (hr) Aklidinij za upotrebu u povećanju fizičke aktivnosti u dnevnom životu kod pacijenta koji pati od kronične opstruktivne bolesti pluća
JP2017511307A5 (ja)
JP2015533131A5 (ja)